pufa 22:5 c

PUFA 22:5 c, also known as docosapentaenoic acid (DPA) or clupanodonic acid, is a long‑chain polyunsaturated omega‑3 fatty acid characterized by a 22‑carbon chain with five cis double bonds. Chemically, DPA is intermediate in the metabolic pathway from eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA) in humans and many other organisms. It is present in phospholipids of cellular membranes, contributing to membrane fluidity, cellular signaling, and lipid mediator synthesis. While EPA and DHA have been more extensively studied for their roles in human health, emerging research suggests that DPA itself has unique biological effects, including potential benefits for cardiovascular health and metabolic regulation. In biochemical pathways, alpha‑linolenic acid (ALA), an essential dietary fatty acid, is first converted to EPA via desaturation and elongation enzymes, then elongated to DPA, and finally to DHA through further enzymatic steps. However, conversion efficiency in humans is low, making dietary intake of long‑chain omega‑3s important. The structure of DPA allows it to be incorporated into cell membranes where it influences physical properties and serves as a substrate for bioactive lipid mediator production. Although not considered 'essential' in the same way as ALA, its presence in diet and tissues underscores a role within the broader family of omega‑3 long‑chain polyunsaturated fatty acids. Research into DPA has been limited compared to its better‑known counterparts, but available data indicate potential roles in modulating inflammation, supporting endothelial function, and influencing lipid metabolism. Because it does not have a defined dietary reference intake, clinical guidelines focus on total omega‑3 fatty acid intake rather than DPA specifically.

Docosapentaenoic acid (DPA) is part of the family of long‑chain omega‑3 polyunsaturated fatty acids that includes EPA and DHA, which are known to influence cardiovascular, metabolic, and inflammatory processes. Although less studied, DPA has unique and overlapping functions compared to EPA and DHA. One recognized function of DPA is its incorporation into cellular membranes, where it helps maintain membrane fluidity and supports the function of membrane‑bound receptors and transporters. Its presence in phospholipids influences signaling pathways crucial for cellular homeostasis. Emerging evidence suggests that DPA may have beneficial effects on cardiovascular risk markers. For example, some studies indicate that higher omega‑3 fatty acid status, including DPA, is associated with improved plasma lipid profiles and reduced risk of myocardial infarction. While specific data for isolated DPA are limited, analyses of diets rich in long‑chain omega‑3s show associations with reduced LDL cholesterol and improved markers of cardiometabolic health. Certain in vitro and animal studies suggest that DPA may exert anti‑inflammatory effects by serving as a substrate for less pro‑inflammatory eicosanoids or resolvins compared to omega‑6 fatty acids, thereby shifting the balance of lipid mediators toward anti‑inflammatory pathways. Additionally, DPA has shown potential in inhibiting platelet aggregation more effectively than EPA in some experimental systems, which could influence thrombosis risk, though human evidence is sparse. Research using DPA‑enriched lipid extracts in mouse models of ulcerative colitis found improvements in gut microbial diversity and reduced indicators of inflammation, suggesting a role in gastrointestinal health through modulation of the microbiota and local immune responses. Another area of interest is the possible association between serum levels of DPA and lower risk for certain neurodevelopmental and mood disorders, though the evidence remains preliminary. DPA may also serve as an intermediate in the synthesis of DHA, a major structural component in the brain and retina, which underscores its contribution to neurodevelopment and visual function indirectly. Because DPA is an intermediary between EPA and DHA, its metabolism is tightly linked to overall omega‑3 fatty acid status, making it part of the broader nutritional strategy that supports cardiovascular and nervous system health through balanced intake of marine‑derived fats.

Unlike essential fatty acids such as alpha‑linolenic acid (ALA), docosapentaenoic acid (DPA, 22:5n‑3) does not have an established Recommended Dietary Allowance (RDA) or Adequate Intake (AI) set by NIH or other major health authorities. Instead, guidelines focus on total long‑chain omega‑3 fatty acids, particularly EPA and DHA, which encompass much of the clinical evidence for health outcomes. Typical recommendations for EPA and DHA intake from organizations like the American Heart Association include at least two servings of fatty fish per week, providing an average of about 250–500 mg/day of combined EPA and DHA, which in practice also increases DPA intake. Thus, while no specific numeric target exists for DPA alone, achieving overall omega‑3 sufficiency through diet is expected to deliver appreciable amounts of DPA along with EPA and DHA. Dietary needs may vary based on age, sex, physiological state, and health status. For example, individuals with cardiovascular disease may be advised by clinicians to aim for higher long‑chain omega‑3 intake. Because DPA is often correlated with EPA/DHA intake in food sources, consumption of oily fish, seafood, and certain animal products that are rich in omega‑3 fatty acids generally supports adequate levels. Factors affecting requirements include metabolic conversion efficiency of ALA to longer chain derivatives, individual genetic variation in desaturase enzymes, and interaction with other nutrients such as antioxidants that protect fatty acids from oxidation. It is important to consider overall dietary patterns rather than focussing on single nutrients, particularly for fats that act synergistically within lipid metabolism. Optimal intakes for overall health outcomes are likely to align with broader omega‑3 fatty acid recommendations, which emphasize dietary sources rather than supplementation in most healthy individuals.

There is no defined clinical deficiency syndrome specific to docosapentaenoic acid (DPA) because it is an intermediate in the omega‑3 metabolic pathway and not classified as an essential fatty acid in isolation. However, low status of long‑chain omega‑3 polyunsaturated fatty acids more generally, which would include low levels of DPA, EPA, and DHA, has been associated with certain risk patterns in population studies. Low omega‑3 status is often reflected in unfavorable ratios of omega‑6 to omega‑3 fatty acids in blood lipids, which is correlated with higher inflammatory markers and greater cardiovascular risk. Clinical signs of long‑chain omega‑3 insufficiency may include dry skin, poor wound healing, mood disturbances, and cognitive changes, but these are nonspecific and not attributable solely to DPA. At‑risk populations for low omega‑3 status, and thus potentially lower DPA, include individuals with very low fish/seafood intake, strict vegetarians/vegans without algae‑derived omega‑3 sources, and those with certain metabolic conditions impairing fatty acid elongation or desaturation. Measurement of omega‑3 index—the percentage of EPA and DHA in erythrocyte membranes—serves as a proxy for overall long‑chain omega‑3 status, though it does not quantify DPA specifically. Because DPA interconverts partially with EPA and participates in the same metabolic pool, low levels are usually seen in the context of generally low long‑chain omega‑3 status. Healthcare providers may evaluate lipid profiles and inflammatory markers to infer possible insufficient intake of long‑chain omega‑3 acids, but specific blood reference ranges for DPA alone are not standardized in clinical practice. Therefore, no clear diagnostic criteria exist for DPA deficiency separate from broader omega‑3 insufficiency.

Docosapentaenoic acid (DPA) is found predominantly in marine foods and certain animal products that are rich in long‑chain omega‑3 fatty acids. While comprehensive USDA tables for DPA are limited, existing nutrient databases show that oily fish, seafood oils, and organ meats provide the highest amounts. For example, seal oil and related traditional marine oils have been reported to contain very high levels of DPA per 100 g serving, followed by menhaden fish oil and salmon oils, which are rich in long‑chain omega‑3s. Wild and farmed salmon, herring, and mackerel contain substantial DPA in their flesh, contributing to daily intakes when these foods are consumed regularly. Shellfish and roe also provide measurable amounts, while beef brain and other organ meats have notable concentrations due to high lipid content. Other animal products such as lamb liver and pork liver contribute moderate DPA levels relative to lean meats. Because DPA is integrated with other omega‑3 fatty acids in phospholipid and triglyceride fractions within foods, its bioavailability is tied to the overall fat content and matrix of the food source. The amounts of DPA vary widely based on species, diet, season, and processing (e.g., smoked v. fresh). Seafood products that are lower in fat, such as whitefish, have lower DPA content compared to oily fish. Preparation methods that retain fats, like grilling or baking with skin on fish, increase the retention of DPA compared to methods that remove fats. Regular consumption of a variety of these foods supports intake of DPA alongside EPA and DHA.

Docosapentaenoic acid (DPA), like other long‑chain polyunsaturated fatty acids, is absorbed in the small intestine through mechanisms similar to those for other dietary fats. It is incorporated into micelles facilitated by bile acids, taken up by enterocytes, and re‑esterified into triglycerides or phospholipids before being packaged into chylomicrons for transport through the lymphatic system into systemic circulation. The presence of dietary fat enhances the absorption of DPA by promoting micelle formation. Conversely, low‑fat meals may reduce micellarization and absorption efficiency. Antioxidants such as vitamin E may protect DPA from oxidative degradation within the gut and circulation, increasing effective bioavailability. Competition with other fatty acids for incorporation into lipoproteins may influence distribution, and the ratio of omega‑6 to omega‑3 fatty acids in the diet can affect metabolic pathways. Once in circulation, DPA is incorporated into cell membranes, particularly in tissues with high lipid turnover.

Given the absence of established RDAs and limited evidence on DPA‑specific supplements, taking supplements of docosapentaenoic acid (DPA) alone is not generally recommended for the average person. However, supplements that contain mixed long‑chain marine omega‑3 fatty acids (EPA/DHA/DPA) are available and may benefit certain individuals, particularly those with low dietary intake of marine sources.

There is no established tolerable upper intake level (UL) for docosapentaenoic acid (DPA) specifically, as clinical research has not defined toxicity thresholds. Long‑chain omega‑3 fatty acids in general are considered safe at typical dietary levels.

Omega‑3 fatty acids including DPA can interact with anticoagulant and antiplatelet medications, potentially increasing bleeding risk.

Common Forms: Marine oil softgels, Algae‑derived omega‑3 oils

Typical Doses: Based on EPA/DHA recommendations (250–500 mg/day)

When to Take: With meals

Best Form: Triglyceride form in mixed EPA/DHA/DPA supplements

⚠️ Interactions: Anticoagulants (e.g., warfarin)